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Abstract 
There remains an unmet need for effective pharmacologic treatments for gastroparesis. 
Ghrelin is the endogenous ligand for the growth hormone secretagogue receptor and has been 
shown to regulate energy homeostasis and exert prokinetic effects on gastrointestinal motility. In 
recent years, several ghrelin receptor agonists have been studied in clinical trials of patients with 
diabetic gastroparesis. The intravenous macrocyclic peptidomimetic, TZP-101 initially suggested 
improvement in gastroparesis symptoms with intravenous administration when compared to 
placebo. However, in subsequent studies of oral preparations, TZP-102 failed to confirm these 
results. Another ghrelin receptor agonist, RM-131 was recently shown to significantly accelerate 
gastric emptying (GE) in patients with type 1 and type 2 diabetes and delayed GE. RM-131 
reduced total Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD) and composite 
scores among type 1 diabetics. Continued development of ghrelin agonists should be explored in 
attempts to expand therapeutic options for the treatment of gastroparesis.
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Introduction 
Gastroparesis is a disorder of gastric motility characterized by a constellation of cardinal 
upper gastrointestinal (GI) symptoms including nausea, vomiting, early satiety or postprandial 
fullness, bloating, and abdominal pain that occurs in association with delayed gastric emptying 
(GE) without mechanical obstruction of the stomach [1]. It is a heterogeneous disorder in which 
different etiologies may impact symptoms or response to treatment. The most common etiologies 
of gastroparesis include diabetes and postsurgical, followed by neurologic, rheumatologic and 
other miscellaneous disorders [2]. However, the etiology is unknown in approximately 40% of 
patients with gastroparesis, a condition identified by idiopathic gastroparesis. Mechanisms that 
contribute to pathophysiology of gastroparesis are variable, and gastric emptying profiles cannot 
specifically distinguish neuropathic from myopathic gastroparesis [3]. Other factors that have 
been implicated in pathogenesis include impaired glycemic control [4], abnormalities of 
interstitial cells of Cajal (ICCs) [5,6], alterations in immune infiltrate marked by increase in 
CD45 and CD68 immunoreactivity [5], decreased heme oxygenase-1 [7,8], and loss of neuronal 
nitric oxide synthase (nNOS) [5,7,9,10].  
The clinical impact of gastroparesis is significant; symptoms, particularly pain, are 
associated with impaired quality of life and increased anxiety or depression [11] while 
examination of national trends has shown a > 200% increase in overall hospitalizations for 
gastroparesis [12]. There remains a need for development of effective and targeted 
pharmacologic treatments.  
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Prokinetic agents should be considered in the pharmacologic treatment of gastroparesis to 
improve gastric emptying and symptoms of gastroparesis [13]. Currently, the only FDA-
approved prokinetic agent in the U.S. remains metoclopramide [14], a potent central and 
peripheral dopamine receptor antagonist that exerts its effects through suppression of the central 
vomiting center and stimulation of gastric motility via receptor-mediated actions resulting in 
increased gastric tone, intragastric pressure, antroduodenal coordination and accelerated gastric 
emptying [15,16]. However, it’s use is limited to short-term treatment (no greater than 12 weeks) 
due to CNS side-effects  such as anxiety, agitation, abnormal movements, dystonic reactions, 
somnolence or confusion, and intractable tardive dyskinesia [17,18]. Other agents include 
domperidone, which is not available in the U.S. but has been made available through a special 
program by the FDA [13]. Eryrthromycin, a motilin receptor, may also be utilized but 
tachyphylaxis remains a limiting factor in its long-term use [17]. More recently, the 28 amino 
acid residue peptide, ghrelin, has been identified as a potential treatment for impaired gastric 
emptying due to its actions on intestinal motility and food intake (reviewed in references 19 and 
20). 
The role of Ghrelin 
 Originally identified in 1999 as the natural ligand for the growth hormone secretagogue 
receptor (GHS-1a) or ghrelin receptor (GRLN-R) [19,20], ghrelin is an orexigenic hormone 
produced mainly in the oxyntic mucosa of the stomach [22] with significant sequence similarity 
to motilin [23]. It is derived from the human ghrelin gene via alternative splicing [24] and 
synthesized from precursor peptides that undergo post-translational processing [25]. The 
majority of circulating ghrelin occurs in the form of deacyl ghrelin which lacks an octanoyl 
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group that is required for the hormone to be biologically active [26]. Octynoylation at serine-3 of 
ghrelin is mediated by O-acyltransferase (GOAT), a polytopic membrane-bound enzyme [27] 
and activation of GRLN-R by biologically active ghrelin results in direct stimulation of pituitary 
growth hormone (GH) release. Both ghrelin and GRLN-R (a G-protein-coupled receptor) are 
widely expressed throughout human tissue [19,28]. Thus, in addition to control of GH secretion, 
ghrelin serves to regulate diverse digestive processes [22], energy homeostasis and food intake 
[29,30], and numerous other systems (reviewed in 19, 28) including the immune system [31]], 
reproductive system [32], cardiovascular system [3334], adrenal glands, neoplastic proliferation, 
and osteoblastic function [35].  
Regulation of energy homeostasis by ghrelin has made ghrelin an appealing target for 
treatment of metabolic disorders including obesity and type 2 diabetes. Ghrelin influences fat 
deposition [36], induces food intake through peripheral and central mechanisms [37] and appears 
to be involved in the rewarding properties of food intake through enhancement of hedonic and 
incentive responses to food-related cues [38]. Fasting expression of ghrelin has been shown to be 
increased by a high fat diet in a mouse model [39] and in patients with anorexia nervosa and 
cachexia, plasma ghrelin levels are increased while lower plasma ghrelin levels are observed in 
obese individuals compared to lean persons or controls [40,41]. Clinical trials in humans 
conducted with ghrelin in cachexia associated with cancer, cardiac and chronic lung disease have 
also shown increases in appetite, weight and cardiac output without significant toxicity [42-44]. 
Effects of ghrelin on gastrointestinal motility 
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 Effects of ghrelin on upper GI functions appear to be mediated through vagal signaling, 
direct stimulation of the enteric nervous system or via direct effects on the CNS after crossing of 
the blood-brain barrier [19]. In vitro studies have demonstrated presence of GRLN-R in enteric 
nervous system of human and animal intestinal preparations [45,46].  Enhanced electrical field 
stimulation (EFS)-induced contractions and a dose-dependent enhancement of the after-
contraction evoked during EFS have been observed with administration of ghrelin to rodent 
stomach strips [45,47,48] via effects that appear to be mediated via cholinergic and tachynergic 
pathways [47,49,50]. Prokinetic effects of ghrelin on GI transit in vivo in rodents have been 
demonstrated with various routes of administration [reviewed in reference 19] in post-surgical, 
opioid-induced, and diabetic models. Administration of acylated ghrelin or ghrelin potentiators 
improved the delayed GE and decreased antral motility in mice exposed to restraint stress [51].  
The role of ghrelin on the migratory motor complex (MMC) has also been studied in 
several animal models to show stimulation of phase II of the MMC via the vagus nerve in the 
house musk shrew, Suncus murinus [52] and induction of a fasted motor pattern, enhancing 
motility of the antrum and duodenum in the fed or fasted state of healthy rodents [53-56]. 
Administration of ghrelin and the endogenous acyl-ghrelin potentiator, rikkunshito, restored fed-
like motor activities to fasted activities in fenfluramine-treated rats and in a cancer anorexia-
cachexia animal model [57]. Meanwhile, consistent reports of effects of ghrelin on colonic 
contractility have been lacking despite tissue expression of GRLN-R [58-62].  Animal studies in 
dogs and rodents have shown no effect on colonic motility with intravenous administration of 
ghrelin, while central or intraperitoneal administration has demonstrated stimulation of colonic 
motility reflected by decreased colonic transit time and increased intracolorectal pressures and 
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fluid output [63-67], suggesting that effects of ghrelin or ghrelin agonists on colonic motility are 
centrally mediated, requiring crossing of the blood brain barrier. 
Studies in healthy human volunteers have shown induction of a premature phase III 
(MMC) using a pharmacologic dose of ghrelin [68] and inhibition of gastric accommodation 
when ghrelin was administered at higher doses was observed by Ang et al., but this was not 
associated with an increase in upper GI symptoms or satiety [69]. Cremonini et al. showed no 
effect on GE of solids or gastric accommodation by single photon emission CT (SPECT) using 
an intravenous bolus synthetic human ghrelin (0.33 μg/kg) that stimulated GH within the 
physiologic range of humans [71]. Meanwhile dosing administration of ghrelin with an infusion 
rate of 10 pmol/kg·min demonstrated acceleration in GE in normal humans in a separate study 
by Levin et al [72].  
Current clinical trials of ghrelin agonists in gastroparesis 
Due to its role in modulation of energy homeostasis and GI motility, ghrelin has been 
identified as a potential treatment for gastroparesis. Abnormal responses to sham feeding with 
impaired increases in systemic ghrelin have been observed in patients with diabetic and 
postsurgical gastroparesis when compared to idiopathic gastroparesis and normal controls [72], 
suggesting that alterations in ghrelin may play a role in gastroparesis. In a randomized, double-
blind, cross-over study, administration of a ghrelin infusion increased GE of a 330 kcal rice-
pudding test meal in seven of ten patients with diabetic gastroparesis and this effect was 
independent of vagal tone [73]. Similar results have been found in a study of six patients with 
idiopathic gastroparesis with enhanced GE and decreased meal-related symptom scores [74] as 
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well as patients with neurogenic gastroparesis using bolus doses of 1 or 4 μg/kg of ghrelin to 
suggest extravagal prokinetic actions of ghrelin [75]. 
Although the potential for ghrelin as a prokinetic agent in the treatment of GI motility 
disorders such as gastroparesis is promising, it is limited by its short half-life [76] and plasma 
instability. Consequently, several synthetic ghrelin agonists have been developed and 
investigated for clinical use. TZP-101 (ulimorelin) is a first-in-class macrocyclic ghrelin 
analogue with potent binding affinity for the ghrelin receptor [77]. Initial investigations of this 
agent in patients with diabetic gastroparesis were promising with 20% reduction in GE half-time 
of solids vs. placebo in a proof of concept study with a trend towards decreased overall 
postprandial symptoms and postprandial fullness (Table 1) [78]. A phase 2 multicenter dose-
ranging study in patients with moderate to severe symptomatic diabetic gastroparesis 
subsequently demonstrated significant improvements from baseline on day 4 in Gastroparesis 
Cardinal Symptom Index (GCSI) loss of appetite and vomiting scores with the 80  μg/kg TZP-
101 dose when compared to placebo and a 25% improvement in GE half-time for a small subset 
of combined TZP-101 dose groups compared to a 8% improvement with placebo, although 
differences in GE T1/2 were not statistically significant (Table 1) [79]. Post-hoc analysis of a 
subset of patients with severe nausea and vomiting (baseline severity score of >3.5 on the GCSI 
Nausea ⁄ Vomiting subscale) enrolled in this phase 2 study found that nausea and vomiting at the 
end of treatment (day 4) were significantly reduced for the 80 μg/kg TZP-101 dose compared to 
placebo and at 30 day follow-up, the improvement of nausea and vomiting appeared to persist for 
the 80 μg/kg and all TZP-101 dose groups (figure 1), although findings did not reach statistical 
significance (Table 1) [80]. No significant safety issues were identified in either the multicenter 
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study or subset population, demonstrating TZP-101to be safe and well tolerated with a relatively 
benign side effect profile [78-80].  
Following TZP-101, oral TZP-102 was developed as a unique synthetic ghrelin receptor 
agonist with a prolonged half-life and promotility activity demonstrated in a rat model of GE 
with dose-dependent increases in GE of up to 51% compared to vehicle. In a phase 2a clinical 
study, 92 patients with diabetic gastroparesis were randomized to once-daily TZP-102 (10, 20, 
40 mg) or placebo. Significant diabetic gastroparesis symptom improvements were observed in 
the GCSI for all TZP-102 doses compared to placebo. In contrast, no significant improvements 
were observed in GE T1/2, the primary efficacy endpoint, with any dose (Table 1) [81]. Two 
phase 2b double-blind, randomized, placebo-controlled clinical trials (studies TZP-102-CL-G003 
and TZP-102-CL-G004) were subsequently conducted to evaluate 12 weeks of once daily and 
three times daily administration of oral TZP-102 in patients with diabetic gastroparesis with the 
primary outcome measure being average change from baseline through end-of treatment in Daily 
Diary of Gastroparesis Symptoms Questionnaire (GSDD). Prior results could not be confirmed 
in these investigations, as improvement in the GSDD were observed in all treatment arms, with 
no significant difference between intervention and placebo. GE analysis showed no significant 
differences in change-from-baseline in Week 12 with treatment or placebo (Table 1). Study TZP-
102-CL-G004 was prematurely stopped due to lack of efficacy in patients with diabetic 
gastroparesis [82].  
Several explanations for the observed lack of efficacy and conflicting results between the 
phase 2a and 2b studies have been proposed: (a) a larger than anticipated placebo-response that 
was more than double that originally anticipated, (b) variations in study design including 
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differences in breath test methods (6h 13C-octanoate testing in the phase 2a study and 3h 3C-
Spirulina platensis testing in the phase 2b study) and diabetes type between the two studies, (c) 
presence of confounding by use of concomitant medications by study participants, (d) a 4-week 
vs. 12-week study duration with lack of durability assessment in the phase 2a study [82,83]. 
Nevertheless, the bottom line that neither study showed efficacy with regards to the primary 
study endpoint remains the same and in conclusion, therapeutic benefits of treatment of TZP-102 
could not be demonstrated. 
RM-131 is a novel pentapeptide ghrelin receptor agonist with 100-fold more potency than 
human ghrelin in reversing gastric ileus in animal [84]. In pre-clinical studies prior to acquisition 
of RM-131 by Rhythm Pharmaceuticals, RM-131 has been shown to cause a dose-dependent 
increase in food intake and weight gain (both fat and lean mass) with greater potency than human 
ghrelin [85]. In a rat models, RM-131 was successful in reversing postsurgical, opiate-induced 
gastric ileus while in normal, nonsurgical primates, RM-131 increased the GE rate [86]. RM-131 
also displayed anti-inflammatory effects and increased survival in models of inflammatory bowel 
disease. In dogs and rodents, treatment with RM-131 showed transient increased in GH levels 
that returned to baseline with continued administration [85].   
The first clinical investigation of RM-131 was performed in women with type 2 diabetes 
and documentation of delayed GE and gastroparesis symptoms to assess pharmacodynamics and 
pharmacokinetic profiles, safety and tolerability of a single dose of RM-131. Results showed that 
compared with placebo, a single subcutaneous injection of RM-131 significantly increased GE 
T1/2 of solids. Improvements in in GE Tlag, GE T1/2 liquids, and colonic filling at 6 hours were 
observed, although not statistically significant. No significant effects was observed for total 
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GCSI-DD score or composite scores for nausea, bloating postprandial fullness and pain; 
however, the study was not powered for these endpoints and baseline symptom severity was not 
a criterion for study eligibility [86].  
A separate study of similar design conducted among patients with type 1 diabetes and 
prior documentation of delayed GE demonstrated that treatment with RM-131 resulted in 
significantly increased early phase GE with decreased gastric retention of solids at 1 hour (p= 
0.005) and 2 hours (p=0.019); however no significant improvement in the primary end point, GE 
T1/2 was observed, possibly due to the small sample size and relatively normal GE T1/2 observed 
in a number of the patients at baseline. Unlike the previous study in patients with type 2 diabetes, 
symptom assessment showed significant reductions in total GCSI-DD and composite nausea, 
vomiting, fullness and pain scores for RM-131 when compared with placebo [87].  
RM-131 was found to be safe and well tolerated in both trials, with no serious adverse 
events reported and no clinically significant impact on physical examination, ECG parameters, 
vital signs, or routine hematology and chemistry laboratory tests [86,87]. Although results of 
initial clinical trials with RM-131 have been promising, larger scale studies will be required to 
address generalizability and establish medium and long-term efficacy of this agent. Currently, 
phase 2 studies are underway among patients with type 1 and type 2 diabetes mellitus and 
gastroparesis to evaluate effects of multiple dosing regimens of RM-131 on gastric emptying and 
gastroparesis symptoms as well as overall safety and tolerability.   
Conclusion 
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 Modulation of ghrelin receptors with novel ghrelin agonists has been identified as a 
pathway for new therapeutic options for the treatment of GI motility disorders such as 
gastroparesis. Prokinetic effects of ghrelin on gastrointestinal motility have been demonstrated in 
through investigation of ghrelin in animal models and human studies of health and diseased 
states leading to clinical trials of several ghrelin receptor agonists in the treatment of 
gastroparesis. The intravenous macrocyclic peptidomimetic, TZP-101 showed initial promise; 
however, efficient acceleration of GE was not clearly shown [78] and a subsequent oral 
preparation of TZP-102 [81] was unable to demonstrate significant improvements in symptoms 
or GE over placebo and thus further study was stopped due to futility. Lack of efficacy of TZP-
102 has brought into question the utility of ghrelin receptor agonists as a useful treatment for 
gastroparesis [88]. However, termination of further investigation of ghrelin agonists would be 
premature as another agent, RM-131 demonstrated efficacy in small clinical trials of patients 
with diabetic gastroparesis with respect to GE endpoints and upper GI symptoms based on 
validated GE assessment by radioscintigraphy and patient-response outcomes by the 
gastrointestinal cardinal symptom index daily diary (GSCI-DD) [89]. These findings will require 
further validation in larger clinical trials to assess responses to multiple dosing regimens of 
longer duration in relevant patient populations.  
 Other points to consider with respect to development of ghrelin agonists are that clinical 
efficacy of these agents may be achieved through effects on alternative mechanisms aside from 
improvement in delayed GE that may be contributing to the pathogenesis of gastroparesis, 
particularly given the known lack of symptom correlation and GE [90]. Future studies of ghrelin 
agonists in the treatment of gastroparesis will also require assessment of effects on other gastric 
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motor functions such as proximal gastric tone and gastric accommodation [69] which may 
accompany changes in GE. Efficacy in the treatment of gastroparesis may also be associated 
with the known antiemetic activity of ghrelin [91-93] and/or its effect on appetite and food intake 
[57,94]. Of note, “hunger” was reported more frequently among patients with type 1 diabetes 
with RM-131 administration [87]. In addition, responsiveness to treatment with ghrelin agonists 
among patients with gastroparesis may vary depending on the underlying etiology of the disease 
and further study among patients with post-surgical and idiopathic gastroparesis will need to be 
explored. Although actions of ghrelin appear to be mediated mainly through vagal signaling or 
directly via the enteric nervous system [19], extravagal effects of ghrelin on gastric motility have 
been show in patients with neurogenic causes of gastroparesis [75].  Furthermore, it has been 
suggested that there exists potential for desensitization of the ghrelin receptor with repeated 
dosing; however, in a study of co-administration of acylated and unacylated ghrelin no 
tachyphylaxis was observed with repeated administration in inducing decreased insulin 
concentrations [95].  
 In summary, ghrelin agonists remain an important area of ongoing clinical investigation 
in the treatment of gastroparesis.   Potential therapeutic application of ghrelin and ghrelin 
agonists remain broad and its effects on gastric motility remain incompletely understood. Early 
clinical trials in small patient populations have shown promising results that will require further 
validation before widespread clinical use. 
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Table 1: Recent clinical trials of synthetic ghrelin agonists in patients with diabetic 
gastroparesis 
Study Intervention Symptom Assessment p-value Gastric Emptying  p-value 
Ejskjaer et 
al. 2009 
[78] 
TZP-101 24% decrease in PP 
symptom intensity and 
37% decrease in PP 
fullness with TZP-101 
ns 20% reduction in 
solid GE T1/2 with 
TZP-101 vs. pcbo 
0.043 
Ejskjaer et 
al. 2010 
[79] 
TZP-101 Mean change from 
baseline in GCSI loss of 
appetite (-2.5 TZP-101, 
-1.6 pcbo)  and 
vomiting (-2.2 TZP-
101, -1.0 pcbo) at day 4 
(secondary endpoint) 
p=0.034; 
p=0.006 
25% change in 
GE T1/2 with 
TZP-101 (subset) 
vs. 8% 
improvement 
with pcbo 
ns 
Wo et al. 
2011 [80] 
TZP-101 (80 
μ/kg) 
Change in mean GCSI 
Nausea/Vomiting and 
Vomiting at day 4 
reduced with TZP-101 
vs. pcbo 
p<0.001; 
p=0.008 
NA NA 
Ejskjaer et 
al. 2013 
[81] 
TZP-102 Improvement in mean 
GSCI total score (-1.2 
with TZP-102; -0.6 
with pcbo) 
p=0.02 No difference in 
GE T1/2 for TZP-
102 vs. pcbo 
ns 
McCallum 
et al. 2013 
[82] 
TZP-102 Improvement in GSDD 
seen in all treatment 
arms 
ns No significant 
difference in 
change from 
baseline with 
TZP-102 or pcbo 
ns 
Shin et al. 
2013 [86] 
RM-131 No significant effects 
for total GCSI-DD 
score or composite 
scores 
ns Faster GE T1/2 
solids with RM-
131 (59.5+7.9) 
vs. pcbo 
(127.8+18.6) 
0.011 
Shin et al. 
2013 [87] 
RM-131 Total GCSI-DD score 
0.17 on RM-131 and 
0.79 on pcbo; lower 
NVFP composite scores 
with RM-131 
p=0.041; 
p=0.041 
Faster GE solids 
at 1 and 2 h with 
RM-131 vs. pcbo.  
p=0.005 
p=0.019  
PP=postprandial; pcbo=placebo; GCSI=Gastroparesis Cardinal Symptom Index; GSDD=Daily 
Diary of Gastroparesis Symptoms Questionnaire; NVFP=nausea, vomiting, fullness, pain  
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Figure Legend 
 
Figure 1: Change in mean Nausea/Vomiting subscale scores (a) and Vomiting scores (b) over 
time. The slopes for days 1–4 in (a) are significantly different for the 80 μg/kg group vs. placebo 
(P<0.001) and All TZP‐101 vs. placebo (P=0.004), and in (b) for 80 μg/kg group vs. placebo 
(P=0.008) and All TZP‐101 vs. placebo (P= 0.005). 
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